Volume 28, Number 10—October 2022
Dispatch
Endofungal Mycetohabitans rhizoxinica Bacteremia Associated with Rhizopus microsporus Respiratory Tract Infection
Shangxin Yang
, Victoria Anikst, and Paul C. Adamson
, Victoria Anikst, and Paul C. Adamson
Table
Antibiotic susceptibility results for Mycetohabitans rhizoxinica isolate from a 65-year-old woman with multiple myeloma undergoing chimeric antigen receptor T-cell therapy admitted to the hospital for worsening foot and ankle pain, California, USA*
| Antibiotic | MIC, µg/mL* |
|---|---|
| Amoxicillin/clavulanate | ≤2 |
| Ceftriaxone | ≤1 |
| Ceftazidime | ≤0.5 |
| Ceftolozane/tazobactam | ≤0.5 |
| Cefepime | ≤0.5 |
| Ceftazidime/avibactam | ≤2 |
| Ertapenem | ≤0.25 |
| Imipenem | ≤1 |
| Meropenem | ≤0.25 |
| Piperacillin/tazobactam | ≤8 |
| Amikacin | 8 |
| Gentamicin | ≤1 |
| Tobramycin | ≤1 |
| Ciprofloxacin | 0.5 |
| Levofloxacin | ≤0.5 |
| Trimethoprim/sulfamethoxazole | ≤1/20 |
*Susceptibility testing was performed on broth-microdilution panels prepared in-house in accordance with CLSI guidelines from the Clinical and Laboratory Standards Institute (https://www.clsi.org).
Page created: September 06, 2022
Page updated: September 21, 2022
Page reviewed: September 21, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
Content Credential